Their study, published October 14 in the journal Cell Metabolism, indicated that auranofin has anti-inflammatory and antidiabetic effects that are independent of each other.

High blood glucose levels are detrimental to many of the body's tissues. Uncontrolled diabetes can lead to organ failure, and insulin resistance is a risk factor for diabetes. Although associations have been established between white adipose tissue inflammation and insulin resistance in humans and rodents, broad anti-inflammatory treatments for diabetes have not shown lasting effectiveness.

In seeking existing drugs to repurpose, computational screening of a small-molecule dataset helped the researchers to identify auranofin. They hypothesized that auranofin's anti-inflammatory properties might help control obesity and diabetes.

The researchers evaluated the metabolic effects of auranofin in mice with diabetes fed a high-fat diet. They discovered that auranofin reduced levels of the hormone leptin, which increases markedly with obesity, contributing to diabetes.

Auranofin also restored white adipose tissue's ability to respond to catecholamines -- signals that increase metabolic activity by triggering the burning of lipids at a higher rate. Further, auranofin normalized hyperinsulinemia, or high blood insulin levels, in the mice.

"These changes coupled together contribute to the overall improvement in insulin sensitivity of the mice, leading to blood glucose control, which is the ultimate goal of diabetes treatments," said first author Dr. Aaron Cox of Baylor.

CHOP spots genetic variants, gene pairings involved in type 2 diabetes
Children's Hospital of Philadelphia (CHOP) researchers used 3D mapping at a microscopic level to identify genetic variants and corresponding target gene...

Sugar alters microbiome, leads to metabolic disease, prediabetes, obesity in mice
Researchers led by Columbia University have investigated the effects of the Western-style high-fat, high-sugar diet on mice and found that while diet...

Researchers identify a key enzyme in synthesis of new class of lipids
Endocrinologists at Beth Israel Deaconess Medical Center have identified a key enzyme in producing a new class of lipids with beneficial effects on insulin...

Targeted nanoparticle delivery provides boost for diabetes transplant
Delivering immunosuppressant treatment via targeted nanoparticles could open the door to a long-lasting cure for type 1 diabetes. Transplanting insulin-producing...

ViaCyte CEO to present at Cell & Gene Meeting
ViaCyte will present data on the latest product candidates the company is developing to treat type 1 diabetes at the Alliance for Regenerative Medicine...